Literature DB >> 432439

Pharmacokinetics of verapamil in man.

Y Koike, K Shimamura, I Shudo, H Saito.   

Abstract

Verapamil was given intravenously (10 mg) and orally (120 mg) in six healthy subjects. After intravenous administration, the serum levels in all subjects declined bi-exponentially. Thereupon, pharmacokinetic parameters were calculated using a two-compartment open model. The half-lives of distribution (T 1/2 alpha) and elimination (T 1/2 beta) phases showed 0.23 hour and 4.21 hour on an average respectively. The apparent volume of distribution [Vd (area)] showed 2.51 1/kg and body clearance (C1b) showed 500.64 ml/min on an average. Renal clearance was smaller than normal human creatinine clearance. After oral administration, the time to reach peak blood level (Tmax) was reached within 1.84 hour and the peak serum concentration showed 219.09 ng/ml on an average. The bioavailability was only 22.47% on an average. Verapamil produced a marked prolongation of PQ interval on electrocardiogram and the degree of PQ interval prolongation was closely related to the increase in serum concentration of this compound. QRS, QTc and RR interval were not changed by this compound.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 432439

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  15 in total

1.  Effect of verapamil on tachycardia-induced early cellular electrical remodeling in rabbit atrium.

Authors:  Roman Laszlo; Christoph Winkler; Stefan Wöhrl; Ralf E Wessel; Sara Laszlo; Mathias C Busch; Jürgen Schreieck; Ralph F Bosch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-09-15       Impact factor: 3.000

2.  Pharmacokinetics of verapamil in patients with renal failure.

Authors:  J Mooy; M Schols; M v Baak; M v Hooff; A Muytjens; K H Rahn
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

3.  Systemic availability of oral verapamil and effect on PR interval in man.

Authors:  A Johnston; C D Burgess; J Hamer
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

4.  Effects of verapamil on P-R-intervals in relation to verapamil plasma levels following single I.V. and oral administration and during chronic treatment.

Authors:  M Eichelbaum; P Birkel; E Grube; U Gütgemann; A Somogyi
Journal:  Klin Wochenschr       Date:  1980-09-15

5.  Simultaneous determination of the intravenous and oral pharmacokinetic parameters of D,L-verapamil using stable isotope-labelled verapamil.

Authors:  M Eichelbaum; A Somogyi; G E von Unruh; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

Review 6.  Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1989-07       Impact factor: 9.546

7.  Plasma levels and myocardial content of verapamil, norverapamil and two N-dealkyl-metabolites in man.

Authors:  R Padrini; E Barbieri; D Piovan; M Toffoli; A Motta; G P Trevi; M Ferrari
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

9.  Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.

Authors:  N T Fuenmayor; B M Faggin; L X Cubeddu
Journal:  Drugs       Date:  1992       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of verapamil.

Authors:  S R Hamann; R A Blouin; R G McAllister
Journal:  Clin Pharmacokinet       Date:  1984 Jan-Feb       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.